IRADIMED CORP
Company Stats
- Market Cap
- $1.1B
- as of Sep 30, 2026
- Shares Outstanding
- 12.8M
- Free Float
- 30.0%
Income Statement
- Revenue
- $83.8M
- Operating Income
- $26.1M
- Net Income
- $22.5M
- EBITDA
- $27.3M
- Revenue Growth, 3Y
- 16.3%
- FCF Margin, 3Y Avg
- 17.9%
- FCF Margin, Worst Year
- 9.2%
Cash Flow
- Free Cash Flow
- $17.2M
- FCF Yield
- 1.6%
- Owner FCF Yield
- 1.3%
Balance Sheet
- Cash & Equivalents
- $51.2M
Returns & Capital
- Dividends Paid
- $15.0M
- Dividend Yield
- 1.4%
- Dividend Payout, 3Y Avg
- 71.6%
- SBC, 3Y Avg
- $2.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $83.8M | $17.2M | 20.5% |
| FY2024 | $73.2M | $17.6M | 24.1% |
| FY2023 | $65.6M | $6.0M | 9.2% |
| FY2022 | $53.3M | $9.2M | 17.3% |
| FY2021 | $41.8M | $10.8M | 25.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges